Uplizna™ (inebilizumab-cdon) injection

Coverage is limited to Uplizna for NMOSD in adults (≥18) who are anti‑aquaporin‑4 (AQP4) antibody positive; AQP4‑negative patients and those under 18 are excluded. Authorization (12 months) requires prescription by or consultation with a neurologist, documented AQP4 seropositivity and age, adherence to the induction (300 mg IV x2 doses 2 weeks apart) then 300 mg IV every 6 months maintenance schedule, and re‑authorization requires documented clinical benefit.

"FDA‑approved indication: Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti‑aquaporin‑4 antibody positive."

Sign up to see full coverage criteria, indications, and limitations.